. home.aspx

home.aspx
   

The Falsified Medicines Directive (FMD) 2011/62/EU

May 30, 2017 / BRIGITTE NAFTALIN

Counterfeit drugs entering the European supply chain pose a significant health and safety threat to patients. Furthermore, the European Union Intellectual Property Office (EUIPO) estimates that the legitimate industry loses approximately €10 billion of revenue annually due to the presence of counterfeit medicines6 in the EU marketplace, corresponding to 4.4% of the sector’s sales.